Business Context and Reporting Period
Company: Koninklijke Philips N.V. (Royal Philips)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Fourth Quarter and Full Year ended December 31, 2025
Filing Date: February 10, 2026
Philips reported full-year 2025 results characterized by growth acceleration, margin expansion, and solid cash flow. The company announced new 2026-2028 financial targets and 2030 Impact Ambitions at its Capital Markets Day. The report covers performance across three segments: Diagnosis & Treatment, Connected Care, and Personal Health.
Key Financial Metrics
| Metric | Q4 2025 | Full Year 2025 | Full Year 2024 |
|---|---|---|---|
| Sales (EUR million) | 5,097 | 17,834 | 18,021 |
| Comparable Sales Growth | 7% | 2% | 1% |
| Comparable Order Intake Growth | 7% | 6% | 1% |
| Income from Operations (EUR million) | 540 | 1,424 | 529 |
| Adjusted EBITA (EUR million) | 770 | 2,195 | 2,077 |
| Adjusted EBITA Margin | 15.1% | 12.3% | 11.5% |
| Net Income (EUR million) | 397 | 897 | (698) |
| Operating Cash Flow (EUR million) | 1,391 | 1,172 | 1,569 |
| Free Cash Flow (EUR million) | 1,200 | 512 | 906 |
| Net Debt (EUR million) | 5,290 | 5,290 | 5,238 |
| Net Debt : Group Equity Ratio | 32:68 | 32:68 | 30:70 |
Material Changes vs. Prior Period
- Profitability Surge: Full-year Income from Operations increased by EUR 895 million (169%) compared to 2024. This was primarily driven by higher gross margins, productivity savings, and a significant reduction in one-time charges compared to the prior year.
- Respironics Impact: The 2024 results were heavily impacted by a EUR 984 million litigation provision and EUR 538 million in insurance income related to Respironics. In 2025, the company made a EUR 1,025 million cash payment for recall-related medical monitoring and personal injury settlements, which impacted Free Cash Flow.
- Margin Expansion: Adjusted EBITA margin improved by 80 basis points for the full year to 12.3%, driven by operating leverage and productivity, offsetting the impact of incremental tariffs.
- Segment Performance:
- Personal Health: Strongest performer with 14% comparable sales growth in Q4 and 8% for the full year. Adjusted EBITA margin reached 23.0% in Q4.
- Connected Care: Recorded 7% comparable sales growth in Q4. Full-year Adjusted EBITA margin improved to 10.7%.
- Diagnosis & Treatment: Flat comparable sales growth (0%) for the full year, though Q4 saw 4% growth. Margins remained stable at 11.7% for the year.
- Productivity: Delivered EUR 0.8 billion in productivity savings in 2025, completing the EUR 2.5 billion target set for the 2023-2025 period.
Guidance, Outlook, and Risks
2026 Outlook
- Comparable Sales Growth: 3% - 4.5%
- Adjusted EBITA Margin: 12.5% - 13.0%
- Free Cash Flow: EUR 1.3 - 1.5 billion
2026-2028 Mid-Term Targets
- Comparable Sales Growth: Mid-single-digit CAGR
- Adjusted EBITA Margin: Mid-teens by 2028
- Cumulative Free Cash Flow: EUR 4.5 - 5.0 billion
- Productivity Savings: EUR 1.5 billion over the period
Management Commentary & Strategy
CEO Roy Jakobs highlighted the company's strengthened core fundamentals and execution agility. The new strategy focuses on three pillars: segment-specific growth strategies, innovation as a key driver (leveraging AI and platform-based solutions), and disciplined execution. The company launched new 2030 Impact Ambitions integrating ESG goals with business strategy.
Risks and Contingencies
- Legal Proceedings: Outlook and targets exclude ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice.
- Macroeconomic Environment: Outlook includes currently known tariffs but notes uncertainty regarding geopolitical tensions and trade actions.
- Operational Risks: Risks include supply chain resilience, cybersecurity, product quality/safety, and the ability to integrate acquisitions.
Investor Verification Checklist
- Respironics Settlements: Verify the status of the EUR 1,025 million payment made in 2025 and potential future liabilities related to the US Department of Justice investigation.
- Tariff Impact: Assess the sensitivity of the 2026 margin guidance to potential increases in tariffs beyond "currently known" levels.
- Free Cash Flow Volatility: Note the significant drop in full-year Free Cash Flow (EUR 512 million) compared to Q4 (EUR 1,200 million) due to the large one-time settlement payment; verify if 2026 guidance assumes no similar large one-off outflows.
- Dividend Structure: Confirm the proposed dividend of EUR 0.85 per share, noting the shareholder option to receive it in cash or shares.
- Acquisition Integration: Monitor the integration of the SpectraWAVE acquisition (completed Jan 2026) and its contribution to the Diagnosis & Treatment segment.